文献速递白血病

维奈克拉联合阿扎胞苷治疗初治急性髓系白血病的真实世界经验

Real-world experience of venetoclax with azacitidine for untreated patients with acute myeloid leukemia.
PubMed 文献 · Blood Adv · 2019-01-01

该单中心回顾性研究比较了33例标签外使用维奈克拉/阿扎胞苷的初治AML患者与33例临床试验中接受同一方案的患者。标签外使用该方案可及性高,且疗效不劣于理论诱导化疗场景,早期死亡率低于预期,并可实现MRD阴性。

要点

  • 标签外维奈克拉/阿扎胞苷可及性高,几乎所有希望使用的患者均可获得。

核心结论

  • 真实世界标签外使用维奈克拉/阿扎胞苷治疗初治AML的结局劣于临床试验环境。
  • 该方案与理论诱导化疗场景相比可能同样有效且毒性更低,早期死亡率低于诱导化疗预期。
  • 接受该方案的患者可实现MRD阴性。
  • 既往暴露于去甲基化药物与更差结局相关。

研究设计与样本

  • 单中心回顾性分析,33例初治AML患者因不适合或不接受诱导化疗而标签外使用维奈克拉/阿扎胞苷。
  • 对照组为同一机构临床试验中接受同一方案的33例患者。
  • 采用微滴式数字PCR评估可测量残留病(MRD)。
  • 与患者接受诱导化疗的理论场景进行比较。

主要发现

  • 既往暴露于去甲基化药物与更差结局相关。
  • 维奈克拉/阿扎胞苷的缓解率不劣于理论诱导化疗场景,且早期死亡率低于诱导化疗预期。
  • MRD阴性可实现。

临床怎么用

  • 对于不适合或不接受诱导化疗的初治AML患者,标签外维奈克拉/阿扎胞苷是可及的治疗选择。
  • 真实世界使用该方案时需注意结局可能劣于临床试验环境,尤其既往暴露于去甲基化药物者。
  • 该方案与诱导化疗相比可能同样有效且毒性更低,早期死亡率更低。
  • 治疗过程中可通过数字PCR监测MRD,MRD阴性可实现。

局限性

  • 单中心回顾性研究,样本量小(每组33例)。
  • 与理论诱导化疗场景的比较非随机对照。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Venetoclax is approved for older untreated acute myeloid leukemia (AML) patients. Venetoclax was available prior to approval off-label. We assessed our single-institution off-label experience with venetoclax/azacitidine, comparing outcomes with a clinical trial cohort that administered this regimen at the same institution. Thirty-three untreated AML patients unfit or unwilling to receive induction chemotherapy and prescribed venetoclax/azacitidine off-trial were retrospectively analyzed and compared with 33 patients who received the same therapy on trial. Outcomes were compared, and comparisons were made to a theoretical scenario in which off-trial patients received induction. Digital droplet polymerase chain reaction evaluated measurable residual disease (MRD). Off-trial venetoclax was attainable in nearly all patients for whom this was desired. The complete remission (CR)/CR with incomplete blood count recovery rate was 63.3% for off-trial patients who received treatment and 84.9% for trial patients (P = .081). The median overall survival for off-trial patients who received treatment was 381 days (95% confidence interval [CI], 174, not reached) vs 880 days (95% CI, 384, not reached) for trial patients (P = .041). Prior exposure to hypomethylating agents was associated with worse outcomes. Response rates with venetoclax/azacitidine were not inferior to a theoretical scenario in which patients received induction, and early death rates were less than expected with induction. MRD negativity was achievable. Newly diagnosed AML patients treated in a "real-world" scenario with off-trial venetoclax/azacitidine had inferior outcomes compared with patients treated in the setting of a clinical trial. Additionally, this therapy may be as effective, and less toxic, when compared with induction chemotherapy.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Winters AC, Gutman JA, Purev E, et al. Real-world experience of venetoclax with azacitidine for untreated patients with acute myeloid leukemia. Blood Adv. 2019. PMID: 31648312. doi:10.1182/bloodadvances.2019000243

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。